Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) is 25.79% higher on its value in year-to-date trading and has touched a low of $10.81 and a high of $21.86 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ICPT stock was last observed hovering at around $15.79 in the last trading session, with the day’s loss setting it -0.23% off its average median price target of $21.00 for the next 12 months. It is also 68.24% off the consensus price target high of $49.00 offered by 16 analysts, but current levels are -29.67% lower than the price target low of $12.00 for the same period.
Currently trading at $15.56, the stock is -19.66% and -13.58% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.62 million and changing -1.46% at the moment leaves the stock -1.24% off its SMA200. ICPT registered 8.28% gain for a year compared to 6-month gain of -7.49%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The stock witnessed a -24.58% loss in the last 1 month and extending the period to 3 months gives it a 6.94%, and is -19.92% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.85% over the week and 5.15% over the month.
Intercept Pharmaceuticals Inc. (ICPT) has around 341 employees, a market worth around $753.42M and $285.70M in sales. Profit margin for the company is 77.60%. Distance from 52-week low is 43.94% and -28.82% from its 52-week high. The company has generated returns on investments over the last 12 months (-37.60%).
Intercept Pharmaceuticals Inc. (ICPT) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Intercept Pharmaceuticals Inc. (ICPT) is a “Hold”. 16 analysts offering their recommendations for the stock have an average rating of 2.70, where 9 rate it as a Hold and 2 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Intercept Pharmaceuticals Inc. is expected to release its quarterly report on 05/10/2023.The EPS is expected to shrink by -20.90% this year
Intercept Pharmaceuticals Inc. (ICPT) Top Institutional Holders
The shares outstanding are 41.56M, and float is at 40.09M with Short Float at 8.14%.
Intercept Pharmaceuticals Inc. (ICPT) Insider Activity
A total of 19 insider transactions have happened at Intercept Pharmaceuticals Inc. (ICPT) in the last six months, with sales accounting for 12 and purchases happening 7 times.
Intercept Pharmaceuticals Inc. (ICPT): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 22.48% up over the past 12 months and Bristol-Myers Squibb Company (BMY) that is -2.54% lower over the same period. MediciNova Inc. (MNOV) is -5.83% down on the 1-year trading charts.
